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Background
Since the side effects during Venom Immunotherapy
(VIT) are associated with several risk factors, we aimed
to evaluate the association of serum basal tryptase (sBT)
levels and of other parameters with the frequency of local
and/or systemic reactions during VIT in children.
Method
Children who underwent conventional VIT due to estab-
lished honeybee or wasp allergy and completed 1-year VIT
were included in the study. Data were collected on sBT
levels, age, sex, culprit insect, degree of preceding sting
reaction, time between last preceding sting reaction and
VIT, venom specific IgE concentration, total IgE levels,
accompanying asthma and aeroallergen sensitization.
Results
We enrolled 45 children with a mean ((± standart
deviation) age of 10.0 ± 3.4 years. VIT with wasp venom
was initiated in 39 patients (87%) and with honeybee
venom in 6 patients (13%). Seventeen patients (37.8%) had
encountered lokal or systemic side effects during VIT.
Side effects were present in 41 out of 1448 injections
(2.8%). There was no significant difference at sBT levels of
children with (4.3 µg/L [3.7-6.3]) or without (4.2 µg/L
[3.1-4.7]) side effects (p=0.303). Multivariate logistic
regression analysis revealed presence of asthma (odds
ratio; [95% confidence interval] (14.2 [2.0–123.5]; p=0.008)
as a significant risk factor for side effects during VIT in
children.
Conclusion
Results of our study determined an association between
accompanying asthma and side effects during VIT.
Patients with asthma may need a particularly high degree
of surveillance during VIT procedure.
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